HLA class II DQA and DQB epitopes: Recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines

Human Immunology

Volumn 74, Issue 9, 2013, Pages 1141-1152

  El Awar, Nadim ^a   Nguyen, Anh ^a   Almeshari, Khalid ^b   Alawami, Moheeb ^b   Alzayer, Fadi ^b   Alharbi, Maha ^b   Sasaki, Nori ^a   Terasaki, Paul I ^c  

^a One Lambda Inc   (United States)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c Terasaki Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; EPITOPE; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN;

ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CLINICAL ARTICLE; ELUTION; HUMAN; IMMUNOADSORPTION; KIDNEY GRAFT; PRIORITY JOURNAL;

ADSORBED AND ELUTED; ADSORPTION/ELUTION; AMR; ANTIBODY-MEDIATED REJECTION; DONOR-SPECIFIC ANTIBODY; DQ ALPHA CHAIN; DQ BETA CHAIN; DQA; DQB; DSA; PBS; PHOSPHATE BUFFERED SALINE; RECOMBINANT HLA CELL LINE; RHLA; ROOM TEMPERATURE, MFI, MEAN FLUORESCENCE INTENSITY; RT; SA; SINGLE ANTIGEN; TG; TRANSPLANT GLOMERULOPATHY;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN PRESENTATION; BINDING SITES, ANTIBODY; CELL LINE; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN BINDING; TRANSGENES;

EID: 84880952533     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.05.013     Document Type: Article

References (17)

1. Deng C.T., El-Awar N., Ozawa M., Cai J., Lachmann N., Terasaki P.I. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008, 86:452.
2. Almeshari K.P.A., Chaballout A., Elgamal H., Almana H., Alzayer F., Abaalkhail N., et al. Targeted monitoring of donor-specific HLA antibodies following renal transplantation. Clinical transplantation 2011, 395-400. Terasaki Foundation Laboratory, Los Angeles. M. Cecka, P.I. Terasaki (Eds.).
3. Al Meshari Khalid, Pall A., Elgamal Hazem, Alzayer Fadi, Al Awwami Moheeb HLA DQ antibodies are the most frequent antibodies encountered in antibody mediated rejection (AMR) of renal allografts. Hum Immunol Suppl 2011, 72:187.
4. Hourmant M., Cesbron-Gautier A., Terasaki P.I., Mizutani K., Moreau A., Meurette A., et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005, 16:2804.
5. Iniotaki-Theodoraki A.G., Boletis J.N., Trigas G., Kalogeropoulou H.G., Kostakis A.G., Stavropoulos-Giokas C.G. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period. Transplantation 2003, 75:1601.
6. Ozawa M., Rebellato L.M., Terasaki P.I., Tong A., Briley K.P., Catrou P., et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clinical transplantation 2006, 265-290. Terasaki Foundation Laboratory, Los Angeles. P.I. Terasaki (Ed.).
7. Willicombe M., Brookes P., Sergeant R., Santos-Nunez E., Steggar C., Galliford J., et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012, 94:172.
8. Worthington J.E., Martin S., Al-Husseini D.M., Dyer P.A., Johnson R.W. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034.
9. DeVos J.M., Gaber A.O., Knight R.J., Land G.A., Suki W.N., Gaber L.W., et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012, 82:598.
10. Anthony Nolan Research Institute Web site. Available at: http://www.anthonynolan.org/HIG/.
11. Amit A.G., Mariuzza R.A., Phillips S.E., Poljak R.J. Three-dimensional structure of an antigen-antibody complex at 2.8A resolution. Science 1986, 233:747.
12. Sheriff S., Silverton E.W., Padlan E.A., Cohen G.H., Smith-Gill S.J., Finzel B.C., et al. Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci USA 1987, 84:8075.
13. National Center for Biotechnology Information Web site. Available at: http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml.
14. Kim C, et al. Crystal structure of Hla-dq2 complexed with deamidated gliadin peptide. http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=26620.
15. El-Awar N., Lee J.H., Tarsitani C., Terasaki P.I. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 2007, 68:170.
16. Duquesnoy R.J., Awadalla Y., Lomago J., Jelinek L., Howe J., Zern D., et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transpl Immunol 2008, 18:352.
17. Kosmoliaptsis V., Sharples L.D., Chaudhry A.N., Halsall D.J., Bradley J.A., Taylor C.J. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011, 91:183.